Common questions about Дигофтон (FAQ)
Q: What is the main difference between Дигофтон and similar medicines?
Regulatory documents describe Digitoxin (the active ingredient in Дигофтон) as having a distinctive and long half-life, which is approximately seven to eight days. This sustained presence in the body is a key differentiating characteristic compared to other cardiac glycosides. Additionally, official sources note that Digitoxin's primary elimination route is hepatic metabolism (processed by the liver), unlike other similar medicines which are mainly cleared by the kidneys.
Q: Is Дигофтон used for other conditions besides the main ones listed?
Official product information is limited to approved indications, such as supporting heart function in Heart Failure and managing heart rate in conditions like Atrial Fibrillation. According to regulatory labels, the medicine is not indicated for the treatment of any other conditions.
Q: How quickly does Дигофтон start working?
The initial administration involves a Loading Dose (or Digitalization) phase, which is administered over 24 to 48 hours. This process is designed to bring drug levels into the therapeutic range. The full stabilization of the medication's benefit is often part of the subsequent long-term maintenance phase.
Q: Can Дигофтон cause weight gain or weight loss?
Official regulatory documents for cardiac glycosides mention that side effects can include unusual weight gain or swelling. This symptom is noted on the label because it may be associated with underlying health changes. Weight loss is not commonly cited in regulatory safety information.
Q: Is it normal to feel tired after starting Дигофтон?
Official information lists drowsiness and extreme fatigue as potential effects. Furthermore, regulatory texts note that non-specific symptoms of toxicity, which may include tiredness, can sometimes be mistaken for symptoms of the patient's underlying heart condition.
Q: Are there any foods or drinks I should avoid while using Дигофтон?
Due to the drug's mechanism, regulatory guidance often stresses that maintaining proper electrolyte balance, particularly potassium, is important for the underlying heart condition being treated. Binding agents, which can include certain high-fiber foods, are officially documented to decrease the medicine’s absorption and may need to be managed with timing constraints.
Q: Can Дигофтон affect my sleep?
Official regulatory texts for this class of medicine list central nervous system (CNS) effects as potential adverse reactions. These effects can sometimes include psychiatric disturbances like insomnia (difficulty sleeping) or general nervousness, particularly if drug levels are elevated or potentially toxic.
Q: Can Дигофтон be used during pregnancy or while breastfeeding?
Official documentation states that use during pregnancy is conditional; it should only be considered when the clinical benefit to the patient is judged to clearly outweigh any possible risks. For breastfeeding, the medicine is described as passing into the milk in small amounts. Official documents note that this is not typically expected to result in adverse effects in the infant, but individual decisions require professional judgment.
Q: Does alcohol change the effect of Дигофтон?
Patient counseling information for related cardiac glycosides advises that alcohol may intensify effects such as drowsiness or dizziness caused by the medication. Regulatory information notes that alcohol consumption should be discussed professionally due to this potential additive effect.
Q: Are there any known interactions between Дигофтон and herbal supplements?
While specific herbal supplements are not always individually listed in regulatory documents, official warnings exist for all substances that affect heart rhythm, potassium levels, or the drug’s metabolism. Certain herbal products can fall into these categories, potentially altering the drug's effect or increasing the risk of toxicity.
Q: Is there a generic version of Дигофтон available?
Official documents identify the active substance in this medication as Digitoxin. Regulatory bodies list multiple approved manufacturers and forms of the active ingredient, indicating that generic versions of Digitoxin are available. However, the specific product name 'Дигофтон' may be a brand name.
Q: What is a 'contraindication' for Дигофтон?
A contraindication is a documented condition or factor that absolutely forbids the use of a medicine because regulatory sources indicate it would cause harm or high risk. For Дигофтон, official labels list specific contraindications, such as the presence of pre-existing ventricular fibrillation.
Q: How does Дигофтон relate to lifestyle changes for the condition it treats?
Regulatory guidance confirms the medication is used as part of a comprehensive management strategy. This strategy often involves addressing the underlying heart condition through measures like diet and weight management, as advised by health professionals.
Q: Can Дигофтон affect my ability to drive or operate machinery?
Official information advises that the medication may cause side effects such as dizziness or drowsiness. Official information indicates that if these effects occur, activities like driving or operating machinery should be avoided until the patient's individual response to the medication is understood.
Q: Can I take Дигофтон if I have a chronic stomach condition?
The drug's official safety profile includes common Gastrointestinal Disorders such as nausea and vomiting. If a patient has a pre-existing chronic stomach condition, careful monitoring is indicated, as the drug's side effects can sometimes complicate or overlap with the symptoms of the existing condition.
Q: Can Дигофтон cause mood changes or depression?
Regulatory texts for cardiac glycosides sometimes list central nervous system effects including confusion, nervousness, and in rare instances, psychiatric disturbances. These potential adverse reactions are generally observed when drug levels are elevated or potentially toxic.
Q: How soon after starting Дигофтон will my doctor assess the results?
Monitoring for the drug begins during the initial 24 to 48 hour Loading Dose period. Official protocols mandate that Therapeutic Drug Monitoring (TDM)—involving laboratory blood checks—be performed to confirm drug levels and guide the transition to the long-term maintenance dose.
Q: What are the ingredients in Дигофтон besides the main active substance?
Official regulatory labels detail both the active ingredient (Digitoxin) and the inactive ingredients (excipients) used in the formulation. Common inactive components listed include substances like cellulose, starch, magnesium stearate, and lactose.
Q: Is Дигофтон gluten-free or lactose-free?
Official composition information indicates that the oral tablet formulation of the medicine often contains lactose (or anhydrous lactose) as an inactive ingredient. Regulatory warnings indicate that due to the presence of lactose, the product should be avoided by patients with rare hereditary problems, such as Lapp lactase deficiency or galactose intolerance.
